The natural compound berberine positively affects macrophage functions involved in atherogenesis

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 2, 2015, Pages 195-201

  Zimetti, F ^a   Adorni, M P ^a   Ronda, N ^a   Gatti, R ^a   Bernini, F ^a   Favari, E ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Atherosclerosis; Berberine; Cholesterol; Inflammation; Macrophages

Indexed keywords

BERBERINE; CHOLESTEROL OXIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; CELL DEATH; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INFLAMMATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; ANIMAL; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; CELL CULTURE; CELL MEMBRANE; CHEMISTRY; DRUG EFFECTS; HYPERCHOLESTEROLEMIA; MACROPHAGE; METABOLISM; SECRETION (PROCESS);

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BERBERINE; CELL MEMBRANE; CELLS, CULTURED; CHEMOKINE CCL2; CHOLESTEROL; HUMANS; HYPERCHOLESTEROLEMIA; MACROPHAGES; MICE; MICE, INBRED C57BL;

EID: 84922012276     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.08.004     Document Type: Article

References (29)

1. Shibata N., Glass C.K. Regulation of macrophage function in inflammation and atherosclerosis. J Lipid Res 2009, (50 Suppl.):S277-S281. 10.1194/jlr.R800063-JLR200.
2. Mahlberg F.H., Glick J.M., Jerome W.G., Rothblat G.H. Metabolism of cholesteryl ester lipid droplets in a J774 macrophage foam cell model. Biochim Biophys Acta 1990, 1045:291-298.
3. Li Y., Schwabe R.F., DeVries-Seimon T., Yao P.M., Gerbod-Giannone M.C., Tall A.R., et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem 2005, 280:21763-21772. 10.1074/jbc.M501759200.
4. Freigang S., Ampenberger F., Spohn G., Heer S., Shamshiev A.T., Kisielow J., et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011, 41:2040-2051. 10.1002/eji.201041316.
5. Qin C., Nagao T., Grosheva I., Maxfield F.R., Pierini L.M. Elevated plasma membrane cholesterol content alters macrophage signaling and function. Arterioscler Thromb Vasc Biol 2006, 26:372-378. 10.1161/01.ATV.0000197848.67999.e1.
6. Adorni M.P., Favari E., Ronda N., Granata A., Bellosta S., Arnaboldi L., et al. Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism. Atherosclerosis 2011, 215:70-76. 10.1016/j.atherosclerosis.2010.12.004.
7. Mulvihill E.E., Huff M.W. Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can J Cardiol 2010, (26 Suppl.). A:17A-21A.
8. Kong W., Wei J., Abidi P., Lin M., Inaba S., Li C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004, 10:1344-1351. 10.1038/nm1135.
9. Dong H., Zhao Y., Zhao L., Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 2013, 79:437-446. 10.1055/s-0032-1328321.
10. Ruscica M., Gomaraschi M., Mombelli G., Macchi C., Bosisio R., Pazzucconi F., et al. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with armolipid plus. J Clin Lipidol 2014, 8:61-68. 10.1016/j.jacl.2013.11.003.
11. Huang Z., Dong F., Li S., Chu M., Zhou H., Lu Z., et al. Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 2012, 690:164-169. 10.1016/j.ejphar.2012.07.009.
12. Guan S., Wang B., Li W., Guan J., Fang X. Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 2010, 38:1161-1169. 10.1142/S0192415X10008548.
13. Huang Z., Meng S., Wang L., Wang Y., Chen T., Wang C. Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-kappaB activation in human THP-1 macrophages. Anat Rec Hob 2012, 295:78-86. 10.1002/ar.21489.
14. Huang Z., Wang L., Meng S., Wang Y., Chen T., Wang C. Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol 2011, 146:153-158. 10.1016/j.ijcard.2009.06.023.
15. Chen F.L., Yang Z.H., Liu Y., Li L.X., Liang W.C., Wang X.C., et al. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine 2008, 33:331-337. 10.1007/s12020-008-9089-3.
16. Markwell M.A., Haas S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978, 87:206-210. doi:0003-2697(78)90586-9.
17. Favari E., Zanotti I., Zimetti F., Ronda N., Bernini F., Rothblat G.H. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 2004, 24:2345-2350. 10.1161/01.ATV.0000148706.15947.8a.
18. Kellner-Weibel G., Luke S.J., Rothblat G.H. Cytotoxic cellular cholesterol is selectively removed by apoA-I via ABCA1. Atherosclerosis 2003, 171:235-243. doi:S0021915003003642.
19. Favari E., Zimetti F., Bortnick A.E., Adorni M.P., Zanotti I., Canavesi M., et al. Impaired ATP-binding cassette transporter A1-mediated sterol efflux from oxidized LDL-loaded macrophages. FEBS Lett 2005, 579:6537-6542. 10.1016/j.febslet.2005.10.042.
20. Zimetti F., Weibel G.K., Duong M., Rothblat G.H. Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res 2006, 47:605-613. 10.1194/jlr.M500466-JLR200.
21. Adorni M.P., Zimetti F., Billheimer J.T., Wang N., Rader D.J., Phillips M.C., et al. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007, 48:2453-2462. 10.1194/jlr.M700274-JLR200.
22. Kruth H.S. Fluid-phase pinocytosis of LDL by macrophages: a novel target to reduce macrophage cholesterol accumulation in atherosclerotic lesions. Curr Pharm Des 2013, 19:5865-5872. doi:CPD-EPUB-20130215-4.
23. McLaren J.E., Michael D.R., Guschina I.A., Harwood J.L., Ramji D.P. Eicosapentaenoic acid and docosahexaenoic acid regulate modified LDL uptake and macropinocytosis in human macrophages. Lipids 2011, 46:1053-1061. 10.1007/s11745-011-3598-1.
24. Kellner-Weibel G., Geng Y.J., Rothblat G.H. Cytotoxic cholesterol is generated by the hydrolysis of cytoplasmic cholesteryl ester and transported to the plasma membrane. Atherosclerosis 1999, 146:309-319. doi:S0021915099001550.
25. Goldstein J.L., Brown M.S. The LDL pathway in human fibroblasts: a receptor-mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul 1976, 11:147-181.
26. Goldstein J.L., Brown M.S. The LDL receptor and the regulation of cellular cholesterol metabolism. J Cell Sci Suppl 1985, 3:131-137.
27. Doherty G.J., McMahon H.T. Mechanisms of endocytosis. Annu Rev Biochem 2009, 78:857-902. 10.1146/annurev.biochem.78.081307.110540.
28. Lee T.S., Pan C.C., Peng C.C., Kou Y.R., Chen C.Y., Ching L.C., et al. Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages. J Cell Biochem 2011, 111:104-110. 10.1002/jcb.22667.
29. Bernini F., Scurati N., Bonfadini G., Fumagalli R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 1995, 15:1352-1358.